PPARG and myeloid sarcoma: In summary, data from EAE studies showed that PPARγ agonists were able to suppress disease severity by regulating the functions of both immune cells and CNS-resident cells (Table 1), supporting PPARγ agonists as an effective treatment of autoimmune demyelinating diseases such as MS.